Dec 12, 2022 / 01:00PM GMT
Operator
Good day, and welcome to the Cogent Biosciences Conference Call. (Operator Instructions)
I would now like to turn the call over to Andrew Robbins, President and CEO.
Andrew R. Robbins - Cogent Biosciences, Inc. - President, CEO & Director
Thank you, and good morning, everyone. Welcome to a special Cogent Biosciences' webcast, in which we're going to provide additional details on the progress of bezuclastinib in advanced systemic mastocytosis patients.
Before we get started, I'd like to remind everyone that along with the other presenters today, I will likely be making forward-looking statements this morning. So we encourage you to review our recent SEC filings, including our Q3 10-Q for a comprehensive discussion about risk factors associated with the company.
With that said, I'd like to introduce myself, Andy Robbins, I'm the CEO of Cogent Biosciences; Dr. Dan DeAngelo, who is the Chief of the Division of Leukemia at the Dana-Farber Cancer Institute; and Dr. Jessica Sachs, who is Cogent's Chief Medical Officer. On today's call,
Cogent Biosciences Inc To Discuss Updated APEX Trial Phase 2 Data at ASH Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot